NeuroPace is a medical device company that develops and commercializes the RNS System, an FDA-approved brain-responsive neuromodulation device designed to treat drug-resistant focal epilepsy by continuously monitoring brain electrical activity, detecting patient-specific seizure patterns, and delivering targeted electrical stimulation to prevent seizures. The company's primary customers are epileptologists and neurosurgeons at comprehensive epilepsy centers and community-based practices who implant the device in adult patients with epilepsy uncontrolled by medication, with revenue generated from device sales and replacement units over the device's battery life, supplemented by reimbursement for programming and data monitoring services through established physician and hospital billing codes covered by commercial insurance and government payors. NeuroPace's competitive advantages include superior tolerability compared to alternative neuromodulation therapies, the ability to record and analyze continuous intracranial EEG data enabling remote patient monitoring and treatment optimization, and a growing dataset of patient records that can be leveraged for artificial intelligence and machine learning applications to enhance therapeutic outcomes.